FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

shington,	D.C. 20549	

OMB APF	PROVAL
OMB Number:	3235-0287
Estimated average	burden

0.5

hours per response:

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						_		. ,				пірапу Асі о	1 1340						
Name and Address of Reporting Person*     Ratcliffe Liam			2. Issuer Name <b>and</b> Ticker or Trading Symbol ARVINAS, INC. [ ARVN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
				[								X Dire	ctor		10% (	Owner			
(Last)	st) (First) (Middle) O ARVINAS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 12/18/2020									Officer (give title Other (specify below) below)					
5 SCIENCE PARK, 395 WINCHESTER AVE.					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	AVEN (	CT	00	6511											X For	m filed by C m filed by M son			
(City)	(	State)	(Z	ip)															
			Table	I - No	n-Deriva	tive S	Secui	rities	Acc	quired	, Dis	posed of	, or B	enefic	ially Ow	ned			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/					Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (ADISPOSED OF (D) (Instr. 3)				nd Securi Benefi	ies cially Following	Form (D) or	: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price	Tropos	tion(s)			(111501.4)	
Common Stock 12/18/20					.020			P		142,857	A	\$70	82	822,857		1 1	See footnote <sup>(1)</sup>		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execusive Or Exercise (Month/Day/Year) if any			if any	eemed Ition Date, h/Day/Year)  4. Transa Code (				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)		e ss ally g d ion(s)	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
			Code	V	(A)	(D)	Date Exerci	eablo	Expiration		Amount or Number of Shares								

## **Explanation of Responses:**

## Remarks:

/s/ Matthew Batters, as attorney-in-fact for Liam Ratcliffe

12/21/2020

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein